pbt maintains position on forbes “neurological dru PRANA...

pbt maintains position on forbes “neurological dru PRANA BIOTECHNOLOGY MAINTAINS POSITION ON
FORBES “NEUROLOGICAL DRUGS TO WATCH” LIST
Melbourne, Australia – February 14, 2005 – Prana Biotechnology Limited (NASDAQ:
PRAN, ASX: PBT), today announced that Forbes.com continues to list PBT1 (Clioquinol) on its
list of “Neurological Drugs to Watch”, which highlights the most promising experimental drugs to
treat diseases of the brain and nervous system.
For more information on Forbes “Neurological Drugs to Watch”, visit:
http://www.forbes.com/sciencesandmedicine/2004/01/26/cx_mh_rl_neurotearsheet.html.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's disease and
other major age-related degenerative disorders. The company was incorporated in 1997 and
listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September
2002. Researchers at prominent international institutions including the University of Melbourne
and Massachusetts General Hospital, a teaching hospital of Harvard Medical School,
discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###
This press release may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995 regarding the Company’s business strategy and future plans of operation. Forward-looking statements involve known and
unknown risks and uncertainties; both general and specific to the matters discussed in this press release. These and other important
factors, including those mentioned in various Securities and Exchange Commission filings made by the Company, may cause the
Company’s actual results and performance to differ materially from the future results and performance expressed in or implied by
such forward-looking statements. The forward-looking statements contained in this press release speak only as of the date hereof
and the Company expressly disclaims any obligation to provide public updates, revisions or amendments to any forward-looking
statements made herein to reflect changes in the Company’s expectations or future events.
Contacts:
Media and Investor Relations
Rebecca Piercy, Buchan
T: +61 3 9866 4722
[email protected]